Clinical trials: Genital Neoplasm
HPV16 Associated Cervical Cancer
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
- Trial name
- NCT02405221
- Testing
- TA-CIN (arm), TA-CIN (thigh)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endometrial Cancer
Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer
Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer: a multicenter prospective randomized study
- Trial name
- SLN_EC (NCT04302714)
- Testing
- Hysteroscopic injection, Cervical injection
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Poly Cystic Ovary Syndrome
Inspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome
Inspiratory muscle training (IMT) is a relatively simple and accessible form of exercise that specifically targets the respiratory muscles and has been reported to improve inspiratory muscle strength, respiratory efficiency…
- Trial name
- NCT07871175
- Testing
- Exercise
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Prostate Cancer
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
This is a prospective, multicentre, open-labelled, randomized controlled trial comparing the efficacy of immediate versus deferred androgen deprivation therapy (ADT) using goserelin (Zoladex®) in men with recurrent prostate…
- Trial name
- ELAAT (NCT00439751)
- Testing
- Goserelin Acetate
- Where
- 11 sites in Canada
- Volunteers
- 79 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy.
- Trial name
- NCT00148772
- Testing
- Erlotinib (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Prostate Cancer
Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA progression times within 5 years for patients with high risk localized Prostate Cancer.
- Trial name
- NCT02107430
- Testing
- Dendritic Cells DCVAC/PCa, Standard radiotherapy
- Where
- 6 sites in Czechia
- Volunteers
- 62 people
- Sponsor
- SOTIO a.s.
Prostate Cancer
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Radical prostatectomy is used to treat early prostate cancer in otherwise well men, but is followed by later cancer relapse in 1 in 4 cases.
- Trial name
- NCT00258765
- Testing
- Zoledronic Acid, Docetaxel
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Ovarian Carcinoma
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer
- Trial name
- NCT05200364
- Testing
- STRO-002, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Sutro Biopharma, Inc.
Prostate Cancer, Neoplasm, Residual
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
The primary objective of this feasibility study is to determine if administration of LUM015 will result in positive fluorescence of tumor tissue from ex vivo specimen imaging with the LUM Imaging device from patients undergoing…
- Trial name
- NCT03441464
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lumicell, Inc.
Prostate Cancer
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
The goal of this clinical research study is to find the highest tolerable dose of PROHIBITIN-TP01 that can be given to patients with advanced prostate cancer for which there are no standard therapy options.
- Trial name
- NCT01262664
- Testing
- Prohibitin-TP01
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal
Avelumab in Refractory Testicular Germ Cell Cancer.
This is a proof-of-concept study to define efficacy of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Conditions
- Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Testicular Diseases
- Trial name
- NCT03403777
- Testing
- Avelumab
- Where
- Slovakia
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute, Slovakia
Adenocarcinoma of the Prostate
Docetaxel and Lycopene in Metastatic Prostate Cancer
Docetaxel is the standard, first-line chemotherapeutic agent for castrate resistant prostate cancer. While it has clinically useful activity, there is a strong need for substantial improvement in its efficacy.
- Trial name
- NCT01949519
- Testing
- Lycopene and Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative
EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
We perform a multicenter randomized controlled prospective study with superiority trial design, in which the polysaccharide ARISTA™ AH hemostat agent is applied to the neurovascular bundle areas after prostate removal, during…
- Conditions
- Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative, Erectile Function
- Trial name
- ARISTA (NCT06822036)
- Testing
- Arm A - Application of 5g of ARISTA™ AH
- Where
- 3 sites in Germany
- Volunteers
- 362 people
- Sponsor
- St. Antonius Hospital Gronau
Ovarian Neoplasms
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
In order to explore the real situation of niraparib in clinical application more comprehensively and deeply, we conducted the first multicenter, real-world study in China.
- Trial name
- NCT05734911
- Testing
- Niraparib
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Zhongda Hospital
Prostate Cancer (Post Prostatectomy)
MRI-guided Brachytherapy and Salvage SBRT Program
Brachytherapy followed by MRI-guided irradiation has the potential to improve treatment results in patients with local relapses after radical prostatectomy
- Trial name
- NCT07132671
- Testing
- Brachytherapy and MR-Guided SBRT
- Volunteers
- 29 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Cervical Cancer
SUV Max as Predictor of Outcome in Cervical Cancer
Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging.
- Trial name
- NCT01262144
- Testing
- Radiotherapy
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Polycystic Ovary Syndrome
The Changes of Body Fat Distribution in Obese Patients With PCOS After LSG
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often…
- Trial name
- NCT04690634
- Testing
- laparoscopic sleeve gastrectomy (LSG)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Shanghai 10th People's Hospital
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer.
- Trial name
- NCT00080899
- Testing
- fenretinide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.